Related Experiment Videos

Hemostatic effects of 1 mg daily warfarin on post CABG patients. Post CABG Studies Investigators

J M Walenga1, D Hoppensteadt, R Pifarré

  • 1Loyola University Medical Center, Maywood, Illinois 60153, USA. jwaleng@luc.edu.

Journal of Thrombosis and Thrombolysis
|June 22, 1999
PubMed

Insights

Low-dose warfarin (1 mg daily) did not alter key blood clotting factors in patients after coronary artery bypass graft surgery. This supports using low-intensity warfarin therapy for managing post-CABG patients.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Hematology

Background:

  • Coronary artery bypass graft (CABG) surgery improves patient outcomes but carries risks of restenosis and graft occlusion.
  • Effective antithrombotic therapy is crucial for long-term success after CABG.

Purpose of the Study:

  • To evaluate the hemostatic effects of low-dose warfarin (1 mg daily) in patients who have undergone CABG.
  • To assess changes in coagulation parameters and risk factors for thrombosis.

Main Methods:

  • A screening study within the Post Coronary Artery Bypass Graft (Post CABG) trial.
  • Paired blood samples were collected from stable post-CABG patients (n=40) before and after 21 days of 1 mg daily warfarin.
  • Assessed prothrombin time, international normalized ratio (INR), prothrombin fragment 1.2, factor VII, von Willebrand's factor, fibrinogen, tPA, and PAI-1.

Main Results:

  • One milligram of daily warfarin did not significantly alter prothrombin time, INR, or prothrombin fragment 1.2.
  • No significant changes were observed in hemostatic risk factors including factor VII, von Willebrand's factor, fibrinogen, tPA, or PAI-1.
  • These findings indicate minimal impact on coagulation markers with this low warfarin dose.

Conclusions:

  • Low-dose warfarin (1 mg daily) appears safe and does not significantly affect key hemostatic markers in stable post-CABG patients.
  • This supports the use of low-intensity warfarin therapy (1-4 mg daily, aiming for INR ≤ 2.0) for managing patients after coronary artery revascularization.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...